The psychopharmacological management of schizophrenia consists primarily of neuroleptics. These drugs have successfully changed the scenario of psychiatry since the 1950s. They have mainly been used for controlling positive symptoms in schizophrenia, but on closer look it is evident that positive and negative symptoms both respond to neuroleptics in the acute and chronic stages of schizophrenia separate reports are cited for acute and chronic stages with an aim to quantitate the response. The early as well as recent studies support these obervations with few exceptions. However, greater responsivity has been observed in the acute stages of schizophrenia
Patients with schizophrenia have profound and disabling cognitive deficits while negative symptoms r...
Patients with schizophrenia have profound and disabling cognitive deficits while negative symptoms r...
Determining the optimal antipsychotic target dose in acute phase treatment is of high clinical relev...
The psychopharmacological management of schizophrenia consists primarily of neuroleptics. These drug...
The psychopharmacological management of schizophre-nia consists primarily of neuroleptics. These dru...
Negative symptoms are highly prevalent in the acute episode and long-term course of schizophrenia. T...
Negative symptoms are highly prevalent in the acute episode and long-term course of schizophrenia. T...
Although negative symptoms were traditionally considered to be unresponsive to neuroleptic medicatio...
Effective treatment of negative symptoms is one of the most important unmet needs in schizophrenic d...
Negative symptoms represent a separate symptom domain, with respect to depression, neurocognition, a...
Negative symptoms represent a separate symptom domain, with respect to depression, neurocognition, a...
Objective: Negative symptoms in schizophrenia are among the most important barriers against rehabili...
The illness of schizophrenia, as it is understood today, appears to consist of a heterogeneous group...
 Objective: Negative symptoms are relatively common with a recent study finding that nearly 58% of ...
The illness of schizophrenia, as it is understood today, appears to consist of a heterogeneous group...
Patients with schizophrenia have profound and disabling cognitive deficits while negative symptoms r...
Patients with schizophrenia have profound and disabling cognitive deficits while negative symptoms r...
Determining the optimal antipsychotic target dose in acute phase treatment is of high clinical relev...
The psychopharmacological management of schizophrenia consists primarily of neuroleptics. These drug...
The psychopharmacological management of schizophre-nia consists primarily of neuroleptics. These dru...
Negative symptoms are highly prevalent in the acute episode and long-term course of schizophrenia. T...
Negative symptoms are highly prevalent in the acute episode and long-term course of schizophrenia. T...
Although negative symptoms were traditionally considered to be unresponsive to neuroleptic medicatio...
Effective treatment of negative symptoms is one of the most important unmet needs in schizophrenic d...
Negative symptoms represent a separate symptom domain, with respect to depression, neurocognition, a...
Negative symptoms represent a separate symptom domain, with respect to depression, neurocognition, a...
Objective: Negative symptoms in schizophrenia are among the most important barriers against rehabili...
The illness of schizophrenia, as it is understood today, appears to consist of a heterogeneous group...
 Objective: Negative symptoms are relatively common with a recent study finding that nearly 58% of ...
The illness of schizophrenia, as it is understood today, appears to consist of a heterogeneous group...
Patients with schizophrenia have profound and disabling cognitive deficits while negative symptoms r...
Patients with schizophrenia have profound and disabling cognitive deficits while negative symptoms r...
Determining the optimal antipsychotic target dose in acute phase treatment is of high clinical relev...